Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies
Authors
Keywords
Uveal melanoma, Ocular melanoma, Immunotherapy, Checkpoint inhibitors, CTLA-4, PD-1, PD-L1, Ipilimumab, Nivolumab, Pembrolizumab
Journal
Current Oncology Reports
Volume 19, Issue 7, Pages -
Publisher
Springer Nature
Online
2017-05-16
DOI
10.1007/s11912-017-0606-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metastatic disease from uveal melanoma: treatment options and future prospects
- (2016) Richard D Carvajal et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies
- (2016) Alain P. Algazi et al. CANCER
- PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
- (2016) M. G. Field et al. CLINICAL CANCER RESEARCH
- The use of pembrolizumab for the treatment of metastatic uveal melanoma
- (2016) Lisa A. Kottschade et al. MELANOMA RESEARCH
- Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
- (2016) Amanda R Moore et al. NATURE GENETICS
- Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis
- (2016) Deborah Kuk et al. ONCOLOGIST
- Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas
- (2016) Matthew G. Field et al. Oncotarget
- Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
- (2016) Ioannis Karydis et al. OncoImmunology
- Epidemiological trends in uveal melanoma
- (2015) Michael T Andreoli et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Identification of an Immunogenic Subset of Metastatic Uveal Melanoma
- (2015) L. D. Rothermel et al. CLINICAL CANCER RESEARCH
- Double-Blinded, Randomized Phase II Study Using Embolization with or without Granulocyte–Macrophage Colony-Stimulating Factor in Uveal Melanoma with Hepatic Metastases
- (2015) Matias E. Valsecchi et al. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- A phase 2 study of tremelimumab in patients with advanced uveal melanoma
- (2015) Anthony M. Joshua et al. MELANOMA RESEARCH
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
- (2015) Lisa Zimmer et al. PLoS One
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4
- (2015) Peter Johansson et al. Oncotarget
- Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients
- (2014) Kalijn F. Bol et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial
- (2014) S. Leyvraz et al. ANNALS OF ONCOLOGY
- Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
- (2014) Richard D. Carvajal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)
- (2013) Sander Kelderman et al. ACTA ONCOLOGICA
- Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
- (2013) M. Maio et al. ANNALS OF ONCOLOGY
- Clinical activity of ipilimumab for metastatic uveal melanoma
- (2013) Jason J. Luke et al. CANCER
- Genetic and clinico-pathologic analysis of metastatic uveal melanoma
- (2013) Klaus G Griewank et al. MODERN PATHOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3
- (2013) Marcel Martin et al. NATURE GENETICS
- Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
- (2013) J William Harbour et al. NATURE GENETICS
- SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma
- (2013) S. J. Furney et al. Cancer Discovery
- Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture
- (2012) B Damato EYE
- Ipilimumab activity in advanced uveal melanoma
- (2012) Muhammad Adnan Khattak et al. MELANOMA RESEARCH
- Detection and Time to Treatment of Uveal Melanoma in the United Kingdom: An Evaluation of 2384 Patients
- (2012) Erika M. Damato et al. OPHTHALMOLOGY
- Ocular Immune Privilege and Ocular Melanoma: Parallel Universes or Immunological Plagiarism?
- (2012) Jerry Y. Niederkorn Frontiers in Immunology
- Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
- (2011) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PRAME-Specific Allo-HLA-Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer
- (2011) A. L. Amir et al. CLINICAL CANCER RESEARCH
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Uveal Melanoma: Trends in Incidence, Treatment, and Survival
- (2011) Arun D. Singh et al. OPHTHALMOLOGY
- Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma
- (2010) Jo Eyles et al. JOURNAL OF CLINICAL INVESTIGATION
- Mutations inGNA11in Uveal Melanoma
- (2010) Catherine D. Van Raamsdonk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophages in uveal melanoma and in experimental ocular tumor models: Friends or foes?
- (2010) Martine J. Jager et al. PROGRESS IN RETINAL AND EYE RESEARCH
- Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
- (2010) J. W. Harbour et al. SCIENCE
- Adjuvant Interferon Therapy for Patients with Uveal Melanoma at High Risk of Metastasis
- (2009) Anne Marie Lane et al. OPHTHALMOLOGY
- Immune escape mechanisms of intraocular tumors
- (2009) Jerry Y. Niederkorn PROGRESS IN RETINAL AND EYE RESEARCH
- Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients
- (2008) Verena Voelter et al. MELANOMA RESEARCH
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
- (2008) Catherine D. Van Raamsdonk et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started